The Expanding Therapeutic Landscape of GLP-1 Receptor Agonists: Beyond Glycemic Control and Weight Management

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of type 2 diabetes mellitus (T2DM) and obesity, demonstrating superior glycemic control and substantial weight loss compared to traditional therapies. These effects stem from their ability to mimic the endogenous GLP-1 hormone, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. However, emerging evidence suggests the therapeutic potential of GLP-1 RAs extends far beyond these established indications. This report provides a comprehensive overview of the multifaceted mechanisms of action of GLP-1 RAs, their various formulations, and delves into the expanding landscape of clinical trials investigating their efficacy in diverse conditions, including cardiovascular disease, neurodegenerative disorders, non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and even potentially in mitigating certain aspects of aging. We critically evaluate the available data, address concerns regarding long-term safety, discuss the differences between various GLP-1 RA molecules and their efficacy profiles, and highlight future directions for research and clinical application. This review aims to provide a comprehensive understanding for experts in the field seeking to leverage the pleiotropic effects of GLP-1 RAs for improved patient outcomes.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its primary role is to regulate glucose homeostasis by stimulating insulin secretion from pancreatic β-cells in a glucose-dependent manner and suppressing glucagon secretion from α-cells. GLP-1 also delays gastric emptying, enhances satiety, and may exert trophic effects on pancreatic β-cells. Due to its short half-life, native GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Consequently, GLP-1 receptor agonists (GLP-1 RAs) were developed to overcome this limitation. These synthetic peptides, or small molecules, bind to and activate the GLP-1 receptor (GLP-1R) with enhanced resistance to DPP-4 degradation, leading to prolonged receptor activation and sustained therapeutic effects.

The initial clinical application of GLP-1 RAs focused on the treatment of T2DM. These agents demonstrated superior glycemic control compared to many traditional therapies, often accompanied by weight loss, a particularly desirable outcome in overweight or obese patients with T2DM. The success of GLP-1 RAs in managing T2DM led to investigations into their potential as weight-loss agents in individuals without diabetes. The subsequent approval of higher-dose GLP-1 RAs specifically for weight management has further solidified their position as a cornerstone of obesity treatment.

However, the story of GLP-1 RAs extends beyond glycemic control and weight management. Preclinical and clinical studies have revealed a wide range of pleiotropic effects, including cardiovascular protection, neuroprotective properties, potential benefits in NAFLD/NASH, and renoprotective actions. This realization has spurred a surge of research exploring the efficacy of GLP-1 RAs in diverse conditions, promising a significant expansion of their therapeutic landscape. This report will delve into these expanding horizons, providing a critical analysis of the current evidence and future directions.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Mechanisms of Action: Beyond Glucose and Appetite

The therapeutic effects of GLP-1 RAs are mediated through the activation of the GLP-1 receptor (GLP-1R), a G protein-coupled receptor (GPCR) expressed in various tissues, including the pancreas, brain, gastrointestinal tract, heart, and kidneys. While the primary actions on glucose homeostasis and appetite are well-established, a deeper understanding of downstream signaling pathways and extra-pancreatic effects is crucial for appreciating the broader therapeutic potential of these agents.

2.1. Pancreatic Effects: Insulin and Glucagon Regulation

The most well-characterized action of GLP-1 RAs is their ability to enhance glucose-dependent insulin secretion from pancreatic β-cells. This glucose dependency is a key advantage, as it minimizes the risk of hypoglycemia compared to sulfonylureas. GLP-1R activation increases intracellular cAMP levels, which in turn activates protein kinase A (PKA) and Epac2. These signaling pathways promote insulin granule exocytosis, leading to increased insulin release. GLP-1 RAs also stimulate β-cell proliferation and inhibit apoptosis, potentially preserving β-cell mass in the long term, although the clinical relevance of this effect remains under investigation.

Simultaneously, GLP-1 RAs suppress glucagon secretion from pancreatic α-cells, particularly during postprandial hyperglycemia. This effect is primarily indirect, mediated by insulin and somatostatin release from neighboring β- and δ-cells, respectively. The reduction in glucagon secretion further contributes to improved glucose control by decreasing hepatic glucose production.

2.2. Gastrointestinal Effects: Gastric Emptying and Satiety

GLP-1 RAs slow gastric emptying, leading to a feeling of fullness and reduced food intake. This effect is mediated by both direct effects on gastric smooth muscle and indirect effects through vagal afferent pathways. The delayed gastric emptying contributes to postprandial glucose control by reducing the rate of nutrient absorption. However, this effect can also contribute to some of the gastrointestinal side effects associated with GLP-1 RAs, such as nausea, vomiting, and diarrhea.

Beyond slowing gastric emptying, GLP-1 RAs also promote satiety by acting on the central nervous system. GLP-1 receptors are expressed in various brain regions involved in appetite regulation, including the hypothalamus and brainstem. Activation of these receptors increases satiety signals and reduces hunger signals, leading to decreased food intake and weight loss. The precise mechanisms by which GLP-1 RAs act on the brain are complex and involve multiple neurotransmitter systems, including dopamine and serotonin.

2.3. Cardiovascular Effects: Beyond Glucose Control

Several large-scale clinical trials have demonstrated that certain GLP-1 RAs significantly reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with T2DM and established cardiovascular disease. The mechanisms underlying these cardioprotective effects are complex and multifactorial, extending beyond glucose control and weight loss. These include:

• Direct effects on the heart: GLP-1R activation in cardiomyocytes may improve myocardial function, reduce oxidative stress, and protect against ischemia-reperfusion injury. However, the expression of GLP-1R in human cardiomyocytes remains a subject of debate.
• Effects on vascular function: GLP-1 RAs improve endothelial function, reduce inflammation, and decrease blood pressure. These effects contribute to improved vascular health and reduced risk of atherosclerosis.
• Effects on lipid metabolism: GLP-1 RAs can improve lipid profiles, reducing triglyceride levels and increasing HDL cholesterol levels. This may contribute to the reduction in cardiovascular risk.
• Effects on blood pressure: While some studies show a modest reduction in blood pressure with GLP-1 RAs, the magnitude of this effect is likely not sufficient to fully explain the observed cardiovascular benefits. The exact mechanisms by which GLP-1 RAs affect blood pressure are still being elucidated.

2.4. Neuroprotective Effects: A Promising Avenue

Emerging evidence suggests that GLP-1 RAs may possess neuroprotective properties, potentially benefiting individuals with neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. GLP-1R activation in the brain can improve neuronal survival, reduce inflammation, and enhance synaptic plasticity. Preclinical studies have shown that GLP-1 RAs can protect against amyloid-beta toxicity, reduce tau phosphorylation, and improve cognitive function in animal models of Alzheimer’s disease. Furthermore, GLP-1 RAs can protect against dopamine neuron loss in animal models of Parkinson’s disease. Clinical trials are underway to investigate the efficacy of GLP-1 RAs in treating these neurodegenerative conditions. The blood-brain barrier (BBB) penetration of different GLP-1RAs is a critical factor for their neuroprotective potential, with some agents showing better penetration than others. The exact mechanisms underlying the neuroprotective effects of GLP-1 RAs are still being investigated but likely involve multiple pathways, including the modulation of inflammation, oxidative stress, and autophagy.

2.5. Effects on Non-Alcoholic Fatty Liver Disease (NAFLD): A Metabolic Synergy

NAFLD is a growing global health problem characterized by the accumulation of fat in the liver in individuals who do not consume excessive amounts of alcohol. It can progress to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation and liver damage, potentially leading to cirrhosis and liver cancer. GLP-1 RAs have shown promising results in treating NAFLD/NASH, likely due to their effects on insulin resistance, weight loss, and inflammation. GLP-1 RAs reduce hepatic steatosis, improve liver enzyme levels, and reduce liver inflammation in patients with NAFLD/NASH. Clinical trials are ongoing to investigate the efficacy of GLP-1 RAs in preventing the progression of NAFLD to NASH and cirrhosis. The mechanisms underlying these beneficial effects include:

• Improved insulin sensitivity: GLP-1 RAs improve insulin sensitivity, reducing hepatic glucose production and lipogenesis.
• Weight loss: GLP-1 RAs promote weight loss, reducing the amount of fat stored in the liver.
• Anti-inflammatory effects: GLP-1 RAs reduce inflammation in the liver, protecting against liver damage.

2.6. Renoprotective Effects: Emerging Evidence in CKD

Chronic kidney disease (CKD) is a major public health problem characterized by a progressive decline in kidney function. Patients with T2DM are at increased risk of developing CKD, and CKD is a major risk factor for cardiovascular disease. Emerging evidence suggests that GLP-1 RAs may have renoprotective effects, potentially slowing the progression of CKD. Several large-scale clinical trials have shown that GLP-1 RAs reduce the risk of macroalbuminuria (a marker of kidney damage) in patients with T2DM and CKD. Furthermore, some studies have shown that GLP-1 RAs can slow the decline in estimated glomerular filtration rate (eGFR), a measure of kidney function. The mechanisms underlying these renoprotective effects are complex and may involve:

• Improved glycemic control: GLP-1 RAs improve glycemic control, reducing the risk of diabetic nephropathy.
• Blood pressure reduction: GLP-1 RAs can lower blood pressure, reducing the strain on the kidneys.
• Anti-inflammatory effects: GLP-1 RAs reduce inflammation in the kidneys, protecting against kidney damage.
• Direct effects on kidney cells: GLP-1 receptors are expressed in kidney cells, and activation of these receptors may have direct protective effects on kidney function. While the expression and specific function in human kidney cells is still under investigation, studies suggest potential for reduced podocyte damage and tubular protection.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. GLP-1 RA Formulations: A Spectrum of Options

Several GLP-1 RAs are currently available, differing in their chemical structure, half-life, route of administration, and efficacy. These differences translate to varying clinical profiles and suitability for individual patients. GLP-1 RAs can be broadly classified into two categories: short-acting and long-acting.

3.1. Short-Acting GLP-1 RAs

Short-acting GLP-1 RAs, such as exenatide and lixisenatide, have shorter half-lives and are typically administered once or twice daily before meals. They primarily exert their effects on postprandial glucose control and gastric emptying. While effective in reducing postprandial glucose excursions, they may have a less pronounced effect on overall HbA1c and weight loss compared to long-acting agents. The shorter duration of action might be preferable for patients experiencing significant gastrointestinal side effects, as the symptoms tend to be less persistent. However, adherence can be more challenging due to the need for multiple daily injections.

3.2. Long-Acting GLP-1 RAs

Long-acting GLP-1 RAs, such as liraglutide, semaglutide, dulaglutide, and exenatide extended-release, have longer half-lives and are administered once weekly or once daily, depending on the specific agent. They provide more sustained glucose control and generally lead to greater HbA1c reductions and weight loss compared to short-acting agents. Semaglutide, in particular, has demonstrated remarkable efficacy in both glycemic control and weight management in clinical trials. The longer duration of action provides convenience and potentially improved adherence, but also means that any side effects experienced can be more prolonged. Oral semaglutide, while technically a long-acting formulation, utilizes a unique absorption enhancer (SNAC) to facilitate oral bioavailability. This formulation offers the convenience of oral administration but requires specific administration instructions (e.g., taken on an empty stomach with a small amount of water) to ensure optimal absorption.

3.3. Choosing the Right GLP-1 RA

The selection of the most appropriate GLP-1 RA for a given patient depends on several factors, including:

• Glycemic control goals: Patients requiring more aggressive glycemic control may benefit from long-acting agents.
• Weight loss goals: Patients seeking significant weight loss may prefer semaglutide or liraglutide.
• Patient preference: Some patients may prefer the convenience of once-weekly injections, while others may prefer the flexibility of daily injections or oral administration.
• Side effect profile: Patients with a history of gastrointestinal intolerance may tolerate short-acting agents better.
• Cost and insurance coverage: The cost of GLP-1 RAs can vary significantly, and insurance coverage may influence the choice of agent.
• Comorbidities: The presence of cardiovascular disease or CKD may favor the use of agents with proven cardiovascular or renal benefits.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Clinical Trials: Expanding the Therapeutic Horizon

Beyond diabetes and obesity, a plethora of clinical trials are currently underway to investigate the efficacy of GLP-1 RAs in diverse conditions. This section highlights some of the most promising areas of research.

4.1. Cardiovascular Disease

As previously mentioned, several GLP-1 RAs have demonstrated cardiovascular benefits in patients with T2DM and established cardiovascular disease. Ongoing trials are investigating whether these benefits extend to individuals without diabetes but at high cardiovascular risk. Furthermore, research is exploring the potential of GLP-1 RAs to prevent heart failure and improve outcomes in patients with established heart failure.

4.2. Neurodegenerative Disorders

Clinical trials are evaluating the efficacy of GLP-1 RAs in treating Alzheimer’s disease and Parkinson’s disease. These trials are assessing the impact of GLP-1 RAs on cognitive function, motor symptoms, and disease progression. Given the limited treatment options for these debilitating conditions, the potential of GLP-1 RAs to provide neuroprotective benefits is particularly exciting. However, the challenges of effectively delivering therapeutic concentrations of GLP-1RAs to the brain remain a significant hurdle.

4.3. Non-Alcoholic Fatty Liver Disease (NAFLD)

Clinical trials are investigating the efficacy of GLP-1 RAs in preventing the progression of NAFLD to NASH and cirrhosis. These trials are assessing the impact of GLP-1 RAs on liver fat content, liver enzyme levels, liver inflammation, and fibrosis. The combination of GLP-1 RAs with other therapies, such as vitamin E or pioglitazone, is also being explored.

4.4. Chronic Kidney Disease (CKD)

Large-scale clinical trials are ongoing to evaluate the renoprotective effects of GLP-1 RAs in patients with T2DM and CKD. These trials are assessing the impact of GLP-1 RAs on kidney function, albuminuria, and the risk of end-stage renal disease. The results of these trials will provide valuable insights into the role of GLP-1 RAs in the management of CKD.

4.5. Other Potential Applications

Beyond the conditions mentioned above, GLP-1 RAs are being investigated for their potential benefits in a range of other conditions, including:

• Polycystic ovary syndrome (PCOS): GLP-1 RAs may improve insulin resistance and menstrual cycle regularity in women with PCOS.
• Sleep apnea: GLP-1 RAs may reduce the severity of sleep apnea by promoting weight loss.
• Substance use disorders: Preliminary studies suggest that GLP-1 RAs may reduce cravings and withdrawal symptoms in individuals with substance use disorders. The potential impact on the reward pathway is being investigated.
• Aging and Longevity: While still in its infancy, research is exploring the potential of GLP-1 RAs to influence lifespan and healthspan by targeting pathways related to metabolism, inflammation, and cellular senescence. However, these studies are primarily preclinical and require further investigation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Safety and Tolerability

GLP-1 RAs are generally well-tolerated, but they are associated with some potential side effects. The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These side effects are typically mild to moderate in severity and tend to diminish over time. However, they can be bothersome for some patients and may lead to discontinuation of treatment.

Rare but potentially serious side effects include pancreatitis, gallbladder disease, and, in animal studies with certain agents, thyroid C-cell tumors. While the risk of pancreatitis appears to be low, clinicians should be vigilant for symptoms of pancreatitis and discontinue GLP-1 RAs if pancreatitis is suspected. The risk of gallbladder disease may be increased in patients taking GLP-1 RAs, particularly those undergoing rapid weight loss. The relevance of the thyroid C-cell tumor findings in animal studies to humans is uncertain. However, GLP-1 RAs are generally contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

It is also crucial to consider potential drug interactions when prescribing GLP-1 RAs. Due to their effect on slowing gastric emptying, GLP-1 RAs can affect the absorption of other orally administered medications. Patients should be advised to take medications that require rapid absorption at least one hour before or after taking GLP-1 RAs. Specifically, careful monitoring is needed when co-administering GLP-1 RAs with medications with a narrow therapeutic index.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Differences in Efficacy and Specificity Between GLP-1 RAs

While all GLP-1 RAs share the same mechanism of action – activation of the GLP-1 receptor – there are notable differences in their efficacy profiles and receptor specificity. These differences can impact clinical outcomes and influence treatment decisions.

6.1. Receptor Binding Affinity and Selectivity

Different GLP-1 RAs exhibit varying affinities for the GLP-1 receptor. Semaglutide and tirzepatide (the latter being a dual GIP/GLP-1 receptor agonist) generally demonstrate higher receptor binding affinities compared to other agents like liraglutide and dulaglutide. Higher affinity may translate to more potent receptor activation and greater therapeutic effects, particularly in terms of weight loss and glycemic control. Furthermore, some GLP-1 RAs might exhibit slight variations in their selectivity for different GLP-1R isoforms or subtypes, although the clinical significance of these variations remains unclear.

6.2. Half-Life and Duration of Action

The half-life of a GLP-1 RA directly influences its duration of action and dosing frequency. Agents with longer half-lives, such as semaglutide and dulaglutide, allow for once-weekly administration, which can improve patient adherence. Shorter-acting agents, like exenatide, may be preferred for patients who experience significant gastrointestinal side effects or those who desire more flexibility in their dosing schedule. The trade-off between convenience and potential side effects is a crucial consideration in selecting the appropriate GLP-1 RA.

6.3. Efficacy in Glycemic Control

Clinical trials have consistently demonstrated that long-acting GLP-1 RAs generally achieve greater reductions in HbA1c compared to short-acting agents. Among the long-acting agents, semaglutide has consistently shown superior glycemic efficacy in head-to-head trials. However, individual responses to different GLP-1 RAs can vary, and some patients may experience better glycemic control with one agent compared to another.

6.4. Efficacy in Weight Loss

Similar to glycemic control, semaglutide has emerged as a particularly potent weight-loss agent. Higher doses of semaglutide specifically approved for weight management have demonstrated remarkable weight reductions in clinical trials. Liraglutide, at its higher dose for weight management, also produces significant weight loss. Other GLP-1 RAs, while effective in promoting weight loss, generally achieve smaller reductions compared to semaglutide and higher-dose liraglutide. The observed differences in weight loss efficacy may be attributed to variations in receptor binding affinity, duration of action, and effects on appetite regulation in the central nervous system.

6.5. Cardiovascular and Renal Outcomes

While several GLP-1 RAs have demonstrated cardiovascular benefits, the magnitude of these benefits may vary between agents. Some agents, like semaglutide and liraglutide, have shown more consistent and robust cardiovascular risk reductions in clinical trials. Similarly, some GLP-1 RAs have demonstrated more pronounced renoprotective effects compared to others. The specific mechanisms underlying these differences in cardiovascular and renal outcomes are still being investigated.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Future Directions

The field of GLP-1 receptor agonism continues to evolve rapidly, with ongoing research exploring novel applications and formulations. Some promising areas for future research include:

• Development of novel GLP-1 RA formulations: This includes the development of oral formulations with improved bioavailability, longer-acting formulations with reduced injection frequency, and combination therapies that target multiple pathways involved in metabolic disease.
• Identification of biomarkers to predict treatment response: Identifying biomarkers that can predict which patients are most likely to benefit from GLP-1 RA therapy would allow for personalized treatment approaches.
• Investigation of the long-term effects of GLP-1 RAs: Long-term safety and efficacy data are needed to fully understand the benefits and risks of GLP-1 RA therapy over several decades.
• Exploration of the potential of GLP-1 RAs to prevent disease: Research is needed to determine whether GLP-1 RAs can be used to prevent the development of T2DM, cardiovascular disease, and other chronic conditions in at-risk individuals.
• Further elucidation of the mechanisms underlying the pleiotropic effects of GLP-1 RAs: A deeper understanding of the mechanisms by which GLP-1 RAs exert their effects on various tissues and organs will facilitate the development of more targeted and effective therapies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

GLP-1 receptor agonists have emerged as a powerful class of therapeutic agents with a wide range of clinical applications beyond diabetes and obesity. Their multifaceted mechanisms of action, including glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite regulation, contribute to their effectiveness in managing metabolic disorders. Emerging evidence suggests that GLP-1 RAs also possess cardiovascular, neuroprotective, and renoprotective properties, opening up new avenues for their use in treating a variety of chronic conditions. While generally well-tolerated, GLP-1 RAs are associated with some potential side effects, and clinicians should carefully consider the risks and benefits before prescribing these agents. Ongoing research is exploring novel formulations and applications of GLP-1 RAs, promising to further expand their therapeutic horizon. The diverse array of GLP-1 RAs available, each with unique efficacy and tolerability profiles, necessitates a personalized approach to treatment selection. As our understanding of the pleiotropic effects of GLP-1 RAs continues to grow, these agents are poised to play an increasingly important role in the management of a wide range of diseases, ultimately improving patient outcomes and quality of life.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in type 2 diabetes – dream come true? Eur J Endocrinol. 2016;174(6):R281-R294. doi:10.1530/EJE-16-0042
2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. doi:10.1152/physrev.00034.2006
3. Garber A. Review of the therapeutic place of the GLP-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2011;13(4):299-309. doi:10.1111/j.1463-1326.2010.01354.x
4. Hussein Y, Eid S, Kurdi M, Fakhri I, Nassar H, Ali O. Effects of GLP-1 receptor agonists on cardiovascular outcomes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):14. doi:10.1186/s12933-021-01441-8
5. Bomberg EM, Husøy A, Grunnet M, Andersen ES. Glucagon-like peptide 1 receptor agonists for neurodegenerative disorders: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(7):909-918. doi:10.1007/s00228-020-02861-7
6. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X
7. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Management in Chronic Kidney Disease Guideline. Kidney Int Suppl. 2020;10(3):1-141.
8. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39. doi:10.1016/S0140-6736(18)32590-X
9. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486
10. Pyke C, Heller RS, Kirk RK, Ørskov C, Holst JJ, Knop FK. GLP-1 receptor localization in monkey and human tissue: pancreas, GI tract, brain, and kidney. Endocrinology. 2014;155(4):1280-1290. doi:10.1210/en.2013-1666
11. Mahapatra MK, Karuppasamy M, Pérez-Potente L, et al. Oral semaglutide. Lancet. 2021;398(10304):975-986. doi:10.1016/S0140-6736(21)01230-0
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
13. Drucker DJ. Glucagon-like peptide-1 receptor agonists and the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929-2940. doi:10.2337/diacare.26.10.2929
14. Trujillo JM. GLP-1 receptor agonists: a review of head-to-head clinical trials. Ther Adv Endocrinol Metab. 2021;12:2042018821995134. doi:10.1177/2042018821995134
15. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates liraglutide-induced weight loss. J Clin Invest. 2014;124(10):4473-4488. doi:10.1172/JCI76032